drugset
drugset / Trial / NCT05216367

Fruquintinib Hepatic Impairment Study

NCT05216367 ↗

Phase 1 Completed 16 enrolled Hutchmed
Non-randomizedSequentialOpen-labelOther

Summary

An Open-label, Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Fruquintinib

Timeline

Start
2022-03-11
Primary completion
2022-10-25
Completion
2022-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 2 mg Oral
Subject Fruquintinib Small molecule 5 mg Oral

Indications

No indication recorded.